Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China; Department of Pharmacy, The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330008, China.
Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Oct 1;1246:124276. doi: 10.1016/j.jchromb.2024.124276. Epub 2024 Aug 20.
Tyrosine kinase inhibitors (TKIs) and triazole antifungals are the first-line drugs for treating chronic myeloid leukemia (CML) and fungal infections, respectively, but both suffer from large exposure differences and narrow therapeutic windows. Moreover, these two types of drugs are commonly used together in CML patients with fungal infections. Multiple studies and guidelines have suggested the importance of therapeutic drug monitoring (TDM) of TKIs and triazoles. Currently, methods for the simultaneous determination of both types of drugs are limited. We developed a simple, rapid, and reliable liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for simultaneous quantification of three commonly used TKIs (imatinib, dasatinib, and nilotinib) and three commonly used triazoles (voriconazole, itraconazole, and posaconazole) in human plasma. The analytes were eluted on a Welch XB-C analytical column (50 × 2.1 mm, 5 µm) at 0.7 mL/min, using a gradient elution of 10 mM ammonium formate (A) and methanol-acetonitrile-isopropanol (80:10:10, v/v/v) containing 0.2 % formic acid (B) with a total analysis time of 3.5 min. The calibration curves were linear over the range from 20 to 4000 ng/mL for imatinib and nilotinib, from 2 to 400 ng/mL for dasatinib, and from 50 to 10,000 ng/mL for voriconazole, itraconazole, and posaconazole. Selectivity, accuracy, precision, recovery, matrix effect, and stability all met the validation requirements. The method was successfully used for TDM in CML patients who co-treated with both TKIs and triazoles. Drug-drug interaction analysis between TKIs and triazoles showed that a significant positive correlation was observed between imatinib and voriconazole, as well as dasatinib and voriconazole. Therefore, this method can be well applied in clinical TDM for patients receiving TKIs, triazoles, or both simultaneously.
酪氨酸激酶抑制剂(TKIs)和三唑类抗真菌药分别是治疗慢性髓性白血病(CML)和真菌感染的一线药物,但两者的暴露差异较大,治疗窗较窄。此外,这两种类型的药物在 CML 合并真菌感染的患者中通常同时使用。多项研究和指南都表明了对 TKI 和三唑类药物进行治疗药物监测(TDM)的重要性。目前,同时测定这两种药物的方法有限。我们开发了一种简单、快速和可靠的液相色谱-串联质谱(LC-MS/MS)方法,用于同时定量测定三种常用 TKI(伊马替尼、达沙替尼和尼洛替尼)和三种常用三唑类药物(伏立康唑、伊曲康唑和泊沙康唑)在人血浆中的浓度。分析物在 Welch XB-C 分析柱(50×2.1mm,5μm)上以 0.7mL/min 的流速洗脱,使用 10mM 甲酸铵(A)和甲醇-乙腈-异丙醇(80:10:10,v/v/v)的梯度洗脱,其中含有 0.2%甲酸(B),总分析时间为 3.5 分钟。伊马替尼和尼洛替尼的校准曲线在 20 至 4000ng/mL 范围内呈线性,达沙替尼的校准曲线在 2 至 400ng/mL 范围内呈线性,伏立康唑、伊曲康唑和泊沙康唑的校准曲线在 50 至 10000ng/mL 范围内呈线性。选择性、准确性、精密度、回收率、基质效应和稳定性均符合验证要求。该方法成功用于同时接受 TKI 和三唑类药物治疗的 CML 患者的 TDM。TKI 和三唑类药物之间的药物相互作用分析表明,伊马替尼和伏立康唑以及达沙替尼和伏立康唑之间存在显著的正相关关系。因此,该方法可很好地应用于同时接受 TKI、三唑类药物或两者治疗的患者的临床 TDM。